Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05577689
Recruiting Observational

Novel Therapy Target in Metastatic Prostate Cancer

NCT05577689 · tracked via the Priya Life Science China tracker
Sponsor
Fudan University
Phase
Observational
Started
2023-08-01
Last updated
2025-06-05

Condition(s) studied

Prostate Neoplasms

Investigational drug(s) / intervention(s)

Tissue

Tissue: Tissue will be derived from patients during a standard of care procedure

Study summary

The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Histologically confirmed prostate cancer 2. metastatic disease confirmed by image examination 3. Patients who can undergo surgery or biopsy for prostate cancer 4. Able to provide informed consent Exclusion Criteria: 1. Patients diagnosed with other types of cancer besides prostate cancer 2. Not accessible to surgery sample 3. Patients fail to provide informed consent 4. Other situation that researchers think are unsuitable for this study

Primary outcome measure(s)

  • Multiple omics features — 3 years
    Multi-omics information including genetic profiling results, transcriptional profiling results and epigenomic profiling results will be collected and analyzed.
  • Organoids successfully generated from metastatic prostate cancer — 3 years
    Successful isolation of prostate cancer organoids from surgical specimens of patients diagnosed with metastatic prostate cancer. We will calculate the culture efficiency and total number of organoids generated in our center.
  • Developing of biomarkers related to cancer metastasis and drug resistant — 3 years
    To search for biomarkers related to tumor metastasis and resistance by performing multi-omics analysis to surgery specimens derived from patients with metastatic prostate cancer.

Trial sites (1)

FacilityCityRegionStatus
Fudan University Shanghai Cancer Center Shanghai Shanghai Municipality Recruiting

More Fudan University trials in China

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) Recruiting
Real-World Study of Young Patients With Solid Tumors in China Recruiting
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer Recruiting
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer Enrolling by invitation
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS) Active, not recruiting

Other trials for the same condition

YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05577689 on ClinicalTrials.gov ↗ ← All trials in China